Ozagrel is an antiplatelet agent classified as a thromboxane A2 synthase inhibitor used to manage conditions such as coronary artery disease and peripheral vascular insufficiency. By selectively inhibiting… Read more
Ozagrel is an antiplatelet agent classified as a thromboxane A2 synthase inhibitor used to manage conditions such as coronary artery disease and peripheral vascular insufficiency. By selectively inhibiting the synthesis of thromboxane A2, the drug reduces platelet aggregation and lowers the risk of cardiovascular events like myocardial infarction and stroke. Within this category, pharmaceutical laboratories can access essential reference standards, including the active pharmaceutical ingredient, identified impurities, metabolites, and stable isotope-labelled compounds. These materials are critical for accurate impurity profiling, method validation, and rigorous quality control throughout the manufacturing process. Researchers and analytical chemists utilize these high-quality standards to ensure the precision of their testing protocols, enabling the detection and quantification of related substances and degradants that may arise during the drug development lifecycle.